Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Respiratory Mucosa

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: Respiratory Mucosa. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-004921-41 Sponsor Protocol Number: P06332 Start Date*: 2015-02-24
    Sponsor Name:Corporation Schering-Plough K.K.
    Full Title: Multicenter, double-blind, randomized, placebo-controlled study of mometasone furoate nasal spray in pediatric subjects with perennial allergic rhinitis
    Medical condition: perennial allergic rhinitis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004922-16 Sponsor Protocol Number: P06333 Start Date*: 2015-02-24
    Sponsor Name:Corporation Schering-Plough K.K.
    Full Title: A study of long-term (12-24 weeks) administration of mometasone furoate nasal spray in pediatric subjects with perennial allergic rhinitis (Protocol No. P06333)
    Medical condition: Perennial Allergic Rhinitis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000854-73 Sponsor Protocol Number: TCN‐032‐002 Start Date*: 2012-06-21
    Sponsor Name:THERACLONE SCIENCES, INC.
    Full Title: A PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TCN-032 (HUMAN MONOCLONAL ANTIBODY DIRECTED AGAINST THE M2 PROTEIN OF INFLUENZA A VIRUS) IN SUBJECTS CHALLENGED WITH H3N2 INFLUENZA A VIRUS
    Medical condition: Treatment of severe influenza A virus disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10070215 Influenza A virus test positive PT
    14.1 10021881 - Infections and infestations 10022002 Influenza A virus infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001259-63 Sponsor Protocol Number: Pollenvaccine2014-01-15 Start Date*: 2016-03-09
    Sponsor Name:Department of Clinical Science, Intervention and Technology, Karolinska Institute
    Full Title: Intralymphatic immunotherapy in increasing doses up to 10 000 SQ-U -a human randomized clinical trial
    Medical condition: Patients with severe to moderate Allegic rhinitis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006319-69 Sponsor Protocol Number: 1.0 Start Date*: 2012-10-25
    Sponsor Name:Pedro Villarejo Campos(Hospital Universitario Ciudad Real)
    Full Title: Closed abdomen hyperthermic intraperitoneal chemotherapy with paclitaxel for advanced epithelial ovarian cancer
    Medical condition: ovarian cancer (II,III,IV FIGO staging and tumoral recurrence)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10028584 Myelosuppression LLT
    14.1 10007541 - Cardiac disorders 10006093 Bradycardia PT
    14.1 10017947 - Gastrointestinal disorders 10028813 Nausea PT
    14.1 10017947 - Gastrointestinal disorders 10012727 Diarrhea LLT
    14.1 10017947 - Gastrointestinal disorders 10047700 Vomiting PT
    14.1 10018065 - General disorders and administration site conditions 10028127 Mucositis LLT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10003239 Arthralgia PT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10001760 Alopecia PT
    14.1 10021881 - Infections and infestations 10046544 Urinary infection LLT
    14.1 10047065 - Vascular disorders 10021097 Hypotension PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10028411 Myalgia PT
    14.1 10021881 - Infections and infestations 10038700 Respiratory infection LLT
    14.1 10029205 - Nervous system disorders 10034610 Peripheral neuropathy NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014290-40 Sponsor Protocol Number: DU176b-D-U305 Start Date*: 2010-02-10
    Sponsor Name:Daiichi Sankyo Development Limited
    Full Title: A phase 3, randomized, double-blind, double-dummy, parallel-group, multi-center, multi-national study for the evaluation of efficacy and safety of (LMW) heparin/edoxaban versus (LMW) heparin/warfar...
    Medical condition: Reduction of the risk of symptomatic recurrent venous thromboembolic complications in patients with acute symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    14.1 10047065 - Vascular disorders 10051055 Deep vein thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) SE (Completed) FR (Completed) EE (Completed) BE (Completed) AT (Completed) ES (Completed) DK (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004889-18 Sponsor Protocol Number: 1.3 Start Date*: 2022-04-21
    Sponsor Name:Medical University of Vienna
    Full Title: Effect of Dupilumab in patients with aspirin-exacerbated respiratory disease (AERD) -A single-center prospective pilot study
    Medical condition: Aspirin-exacerbated respiratory disease (AERD), also known as Samter's Triad or Widal's triad, comprises the triad of allergic asthma, chronic rhinosinusitis with nasal polyps (CRswNP) and nonstero...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000361-78 Sponsor Protocol Number: HTA-HUR-01 Start Date*: 2020-12-01
    Sponsor Name:HOLOSTEM TERAPIE AVANZATE S.R.L.
    Full Title: PROSPECTIVE, OPEN-LABEL, UNCONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF AUTOLOGOUS CULTURED ORAL MUCOSA GRAFTS FOR URETHRAL RECONSTRUCTION IN PATIENTS DUE TO HYPOSPADIAS TREATMENT...
    Medical condition: Urethral reconstruction in patients due to hypospadias treatment failure.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002189-38 Sponsor Protocol Number: 44945 Start Date*: 2017-10-11
    Sponsor Name:Erasmus Medical Center
    Full Title: OPTIMIZING PERIPHERAL CIRCULATION WITH VASODILATOR THERAPY IN CRITICALLY ILL PATIENTS WITH CIRCULATORY SHOCK: A PILOT STUDY
    Medical condition: Circulatory shock
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000582-13 Sponsor Protocol Number: RO-2455-402-RD Start Date*: 2012-03-05
    Sponsor Name:Takeda Development Centre Europe Ltd.
    Full Title: A 16-week, randomized, placebo-controlled, double blind, and parallel group trial to assess the anti-inflammatory effects of Roflumilast in chronic obstructive pulmonary disease The ROBERT study ...
    Medical condition: severe chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) SE (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002450-24 Sponsor Protocol Number: MV130-SLG-002 Start Date*: 2012-10-09
    Sponsor Name:Inmunotek S.L.
    Full Title: Randomized double-blind placebo-controlled prospective, parallel, single centre clinical trial of bacterial vaccine (BACTEK ®) sublingual (oral mucosa) in patients with repeat bronchospasm for the...
    Medical condition: Recurrent bronchospasm
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006482 Bronchospasm PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-004958-29 Sponsor Protocol Number: CHUBX2019/25 Start Date*: 2020-04-07
    Sponsor Name:CHU de Bordeaux
    Full Title: EFFECT OF POLYETHYLENE GLYCOL TREATMENT ON INTESTINAL INFLAMMATION ASSOCIATED WITH CYSTIC FIBROSIS IN CHILDREN
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000292-16 Sponsor Protocol Number: HULPTOR-2011-01 Start Date*: 2013-06-28
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario La Paz (FIBHULP)
    Full Title: Phase IIa clinical trial to test the feasibility and safety of using autologous mesenchymal stem cells from fat in the local treatment of bronchopleural fistula
    Medical condition: Bronchopleural fistula
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-009154-25 Sponsor Protocol Number: omalizumab/2009/01 Start Date*: 2009-07-07
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St.Thomas' NHS Foundation Trust
    Full Title: The effect of a humanised monoclonal anti-IgE antibody (omalizumab) on disease control and bronchial mucosal inflammation in non-atopic (“intrinsic”) asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003768-31 Sponsor Protocol Number: NNF18OC0052256 Start Date*: 2019-12-05
    Sponsor Name:Lungemedicinsk Forskningsenhed
    Full Title: Effects of azithromycin treatment on anti-viral immunity in patients with asthma and COPD.
    Medical condition: COPD and asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000186-76 Sponsor Protocol Number: MK-4117-200 Start Date*: 2017-01-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects with Perennial Allergic Rhinitis.
    Medical condition: Perennial allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001381-15 Sponsor Protocol Number: RICH-ART Start Date*: 2012-06-13
    Sponsor Name:Sahlgrenska University Hospital Västra Götalandsregionen
    Full Title: Radiation Induced Cystits treated with Hyperbaric Oxygen. A Randomized controlled Trial
    Medical condition: Radiation Cystitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10057480 Hyperbaric oxygen therapy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000060-20 Sponsor Protocol Number: 2018-08-EFT-1 Start Date*: 2019-12-20
    Sponsor Name:HEXAL AG
    Full Title: Efficacy and safety of acetylcysteine for the treatment of acute uncomplicated rhinosinusitis: a prospective, randomized, double-blind, placebo-controlled trial
    Medical condition: Acute rhinosinusitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10052106 Rhinosinusitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-003253-28 Sponsor Protocol Number: MV130-SLG-001 Start Date*: 2012-12-13
    Sponsor Name:Inmunotek S.L.
    Full Title: Randomized double-blind placebo-controlled prospective, parallel, multicentre clinical trial of bacterial polivalent vaccine (BACTEK ®)administered by sublingual mucosa in subjects with chronic o...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-000267-72 Sponsor Protocol Number: D3252C00002 Start Date*: 2021-09-07
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps ...
    Medical condition: Patient with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) IT (Ongoing) SE (Ongoing) BG (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:26:29 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA